Contents

Volume 77 Issue 2 | ARD February 2018

Editorial

159  Bout of the corner men and not the boxers? Contextual effects flex their muscles
M England

Viewpoint

162  The evolving role of the rheumatologist in the management of immune-related adverse events (iAEs) caused by cancer immunotherapy
L Calabrese, X Marianne

Recommendation

165  Consensus-based recommendations for the use of biosimilars to treat rheumatoid diseases
J Kay, M M Scheols, T Dörner, P Emery, T K Kvien, J S Smolen, F C Breeveld, on behalf of the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases

Review

175  Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
K F Baker, J D Isaacs

Clinical and epidemiological research

188  Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial

212  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

221  Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
M De Pauw, W P Maksymowych, R B M Landew, A Mohi, P Claudepierre, M de Hooge, R G Lambert, R Bonin, J F Bukowski, H E Jones, J Logean, R Pedersen, A Szumski, B Vlahos, D van de Heijde

234  Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

196  Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses’ Health Study cohorts
M Barbhaiya, S K Tedeschi, B Lu, S Malspeis, D Kreps, J A Sparks, E W Karlson, K H Costenbader

203  Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants
J Rönnefeld, M Hansson, L Mattsson-Abn, M Cornillet, E Reed, P J Jakobsson, L Alfredsson, R Holmähl, K Skriner, G Serne, K Lundberg, L Klareskog

MORE CONTENTS ▶
Contents

Volume 77 Issue 2 | ARD February 2018

241 Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
L J McCann, C A Pilkington, A M Huber, A Ravelli, D Appelbe, J J Kirkham, P R Williamson, A Aggarwal, L Christopher-Smith, T Constantin, B M Feldman, I Lundberg, S Maillard, P Mathiesen, R Murphy, L M Pachman, A M Read, L G Rader, A van Ruyen-Kerkof, R Russo, S Sprent, L R Wedderburn, M W Beresford

251 Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
L J van Mens, M G H van de Sande, A W R van Kuijk, D Baeten, L C Coates

258 Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire

264 Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study
C. Götstam Skorpen, S Lydersen, I-M Gilboe, J F Skovsmøll, K A Seljesen, Øvind Palm, H S Svanek Koksvik, B Jakobsen, M Wallenius

270 Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study
H Yamanaka, S Tamaki, Y Ide, H Kim, K Incse, M Sugimoto, Y Hidaka, A Taniguchi, S Fujimori, T Yamamoto

277 Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study
R Charlton, A Green, G Shaddick, J Snowball, A Nightingale, W Tillett, C H Smith, N McHugh, on behalf of the PROMPT study group

281 Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers
R L Cordt, K Zobbe, P Højgaard, L E Kristensen, S Overgaard, A Økgjærd, H Lindegaard, I Dreyer

289 Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
A Kavankaugh, R F van Vollenhoven, R Fleischmann, P Emery, J Sainsbury, S Florennins, S Chen, B Guérin, H Kapper, J Masol

293 Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort
A de Konig, F de Bruin, R van den Berg, S Ramiro, X Baraliakos, J Braun, F A van Gatelen, M Reijerse, D van der Heijde

Basic and translational research

300 Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint

Letters

310 Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
R Wittek, P Carron, B Lambert, P Meeusman, G Verbruggen, F Van den Bosch, D Elewaat

311 The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases

313 Plasma oxypurinol as a measure of adherence in clinical trials
L K Stam, T Merrinou, C Frampton, M Zhang, M Wallace, J N Miner, N Dalbeth

315 Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis
C Deng, A Bianchi, N Presle, D Moulin, M Kajano, C Guillaume, H Kempj, A Pizard
## Electronic pages

### Correspondence

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>e6</td>
<td>Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis</td>
<td>M Samson, T Ghesquière, S Berthier, B Bonnotte</td>
</tr>
<tr>
<td>e7</td>
<td>Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al</td>
<td>R Conway, U Fearon, E S Molloy</td>
</tr>
<tr>
<td>e8</td>
<td>ANCA-associated vasculitis: mission incomplete</td>
<td>S V Moiseev, P I Novikov, I Smitienko</td>
</tr>
<tr>
<td>e10</td>
<td>Comment on CONCEPT by Reginster et al: are the authors’ interpretations supported by the data analysis?</td>
<td>S Kardesz</td>
</tr>
<tr>
<td>e11</td>
<td>CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis</td>
<td>J-Y L Reginster, on behalf of CONCEPT Investigation Group</td>
</tr>
</tbody>
</table>